Last updated: September 8, 2026
Follitropin alfa is a mature recombinant follicle-stimulating hormone used in controlled ovarian stimulation, ovulation induction, and spermatogenesis treatment. The originator product, Gonal-f, remains commercially important, but its growth profile is constrained by generic and biosimilar competition, expanded use of lower-cost urinary gonadotropins, fertility-treatment reimbursement pressure, and the absence of meaningful global volume growth in the mature assisted-reproduction market. Merck KGaA does not disclose standalone Gonal-f revenue, so the product’s financial trajectory must be assessed through Merck Serono segment results, market-share trends, pricing, and competitor launches.
What is follitropin alfa and how is it used?
Follitropin alfa is recombinant human follicle-stimulating hormone, or FSH. It is produced using recombinant DNA technology and is structurally comparable to endogenous human FSH, although glycosylation and manufacturing processes affect pharmacokinetic and pharmacodynamic characteristics.
The principal branded product is Gonal-f, marketed globally by Merck KGaA through its healthcare business and regional affiliates. Approved uses include:
- Ovarian stimulation in women undergoing assisted reproductive technology, including in vitro fertilization.
- Ovulation induction in anovulatory women.
- Stimulation of spermatogenesis in men with hypogonadotropic hypogonadism, usually with human chorionic gonadotropin therapy.
Gonal-f is supplied mainly as multidose or prefilled pen presentations. The pen format supports home administration and has helped preserve brand preference in fertility clinics.
| Product |
Active ingredient |
Primary sponsor or marketer |
Main use |
| Gonal-f |
Follitropin alfa |
Merck KGaA / EMD Serono |
Ovarian stimulation and male hypogonadotropic hypogonadism |
| Bemfola |
Follitropin alfa |
Gedeon Richter |
Biosimilar ovarian stimulation product |
| Ovaleap |
Follitropin alfa |
Theramex / formerly Teva-linked commercialization |
Biosimilar ovarian stimulation product |
| Follistim AQ |
Follitropin beta |
Organon |
Recombinant FSH competitor |
| Rekovelle |
Follitropin delta |
Ferring |
Recombinant FSH with individualized dosing |
| Menopur |
Menotropins |
Ferring |
Urinary-derived gonadotropin competitor |
The European Medicines Agency authorized Ovaleap in 2013 and Bemfola in 2014 as biosimilar versions of Gonal-f. [1,2] The products compete primarily on price, clinic procurement, pen usability, and reimbursement rather than on major clinical differences.
How large is the follitropin alfa market?
The global market for follitropin alfa is part of the broader fertility-drug and gonadotropin market. Public company disclosures generally do not separate Gonal-f sales from other reproductive-health products, making precise product-level market sizing unavailable from audited filings.
Market demand is driven by:
- Growth in assisted reproductive technology procedures.
- Delayed childbearing and declining fertility rates.
- Increased diagnosis and treatment of infertility.
- Greater use of elective fertility preservation.
- Public and private reimbursement for IVF.
- Expansion of fertility clinics in Asia-Pacific, Latin America, and the Middle East.
Demand is limited by treatment affordability. IVF cycles often require multiple medication courses, and gonadotropins can represent a material portion of the cycle cost. Payers and clinics therefore have incentives to substitute lower-cost biosimilars or urinary products where clinical protocols permit.
The market is concentrated in the United States, Western Europe, Japan, China, Australia, and major fertility hubs in the Middle East. Europe has generally experienced earlier biosimilar penetration because national health systems and clinic tenders place greater emphasis on acquisition cost. The United States has retained a stronger branded-product structure, although specialty-pharmacy and payer controls have increased price pressure.
What is the financial trajectory of Gonal-f and follitropin alfa?
Gonal-f is a mature revenue product rather than a high-growth asset. Its financial trajectory has four phases:
| Period |
Commercial position |
Financial effect |
| Initial launch and adoption |
Replacement of urinary FSH in fertility protocols |
Rapid uptake and premium pricing |
| Expansion phase |
Broader IVF adoption and pen-based administration |
Strong revenue growth |
| Patent and exclusivity maturity |
Entry of biosimilar follitropin alfa in Europe |
Price and share erosion |
| Mature-market phase |
Stable fertility demand with tender and reimbursement pressure |
Low growth or gradual decline, offset by geographic expansion |
Merck KGaA reports healthcare performance at business-segment level and does not provide a standalone Gonal-f revenue line in its annual reporting. [3] As a result, the product’s exact annual revenue, gross margin, and regional contribution cannot be calculated from public company filings without proprietary market data.
The economic characteristics remain attractive despite maturity:
- Manufacturing is technically complex and requires validated cell-line, fermentation, purification, and glycosylation controls.
- Fertility treatment is specialist-led, supporting prescription persistence.
- Pen devices create switching friction.
- Treatment courses are recurring for patients undergoing multiple cycles.
- The product has a recognized global brand and extensive clinical use.
The principal financial risks are lower net pricing, biosimilar substitution, tender losses, and therapeutic substitution by follitropin delta, follitropin beta, and menotropins.
When does follitropin alfa lose exclusivity?
The core composition-of-matter and manufacturing patent protection for first-generation recombinant follitropin alfa products has largely expired or become commercially ineffective in major markets. The competitive transition began before the 2020s, with European biosimilar approvals for Ovaleap and Bemfola.
Patent expiry does not automatically produce immediate generic entry for biologics. Market access also depends on:
- Regulatory approval under a biosimilar or follow-on biologic pathway.
- Availability of reference-product data.
- Manufacturing capacity and quality-system compliance.
- Device and presentation requirements.
- National reimbursement and substitution rules.
- Patent disputes involving formulations, devices, methods of use, or manufacturing processes.
The remaining commercial protection for Gonal-f is therefore based more on brand equity, clinical familiarity, device design, manufacturing know-how, distribution, and physician preference than on a single blocking composition patent.
What patents protect follitropin alfa products?
Protection for recombinant FSH products has historically covered several layers:
Active biological molecule
Early patent families covered recombinant production of human FSH, nucleotide sequences, host cells, and expression systems. These foundational rights generally have expired in the major markets where Gonal-f has been sold for decades.
Manufacturing methods
Manufacturing patents and proprietary know-how can cover:
- Recombinant host-cell systems.
- Cell-culture conditions.
- Purification and viral-clearance steps.
- Glycosylation control.
- Potency and impurity specifications.
- Batch consistency and formulation stability.
These rights can remain commercially relevant even after basic molecule patents expire because biosimilar sponsors must independently establish a robust manufacturing process.
Formulations and delivery devices
Gonal-f’s prefilled pen and multidose systems create possible protection around:
- Cartridge construction.
- Dose-setting mechanisms.
- Injection components.
- Stability during refrigerated storage.
- Concentration and excipient combinations.
- User-interface design.
Device and formulation patents rarely prevent all biologic competition, but they can delay direct substitution or support differentiated presentations.
Method-of-use patents
Method patents can address ovarian stimulation protocols, dose adjustment, patient selection, and administration schedules. Their practical value is limited when physicians can use an approved product under a different protocol or rely on label-based treatment methods not covered by a surviving patent.
What is the FDA regulatory status of follitropin alfa?
Gonal-f is FDA-approved as a biologic product for infertility treatment. In the United States, biologic competition is governed primarily by the Public Health Service Act and the FDA’s biosimilar pathway under section 351(k). [4]
The U.S. regulatory environment differs from Europe in three respects:
- Biosimilar approval requires a reference-product relationship and a totality-of-evidence showing.
- Interchangeability is a separate designation from biosimilarity.
- Pharmacy-level substitution depends on federal and state law.
The existence of European biosimilar follitropin alfa products does not establish that those products are FDA-approved or automatically substitutable in the United States. Gonal-f’s U.S. commercial position has therefore been more insulated than its European position, although payer-driven substitution remains a risk.
Which companies are challenging the Gonal-f franchise?
Competition comes from both direct follitropin alfa biosimilars and alternative FSH products.
| Competitor |
Product type |
Competitive mechanism |
| Gedeon Richter |
Bemfola, follitropin alfa biosimilar |
Lower-cost direct competition in Europe and other markets |
| Theramex and regional partners |
Ovaleap, follitropin alfa biosimilar |
Direct biosimilar competition |
| Organon |
Follistim AQ, follitropin beta |
Brand competition within recombinant FSH |
| Ferring |
Rekovelle, follitropin delta |
Individualized dosing and differentiated clinical positioning |
| Ferring |
Menopur, menotropins |
Urinary-derived gonadotropin alternative |
| Local manufacturers |
Recombinant or urinary gonadotropins |
Price competition in emerging markets |
Follitropin delta has a distinct competitive proposition because dosing is individualized using anti-Müllerian hormone and body weight. [5] This can shift the treatment decision away from a direct price comparison with follitropin alfa.
Are there Paragraph IV challenges to Gonal-f?
Publicly visible U.S. Paragraph IV litigation has not created a widely reported, market-defining challenge comparable to major small-molecule blockbusters. The reason is structural: biologic competitors generally proceed through the biosimilar framework rather than the traditional ANDA Paragraph IV pathway used for small-molecule generics.
A biosimilar applicant may still contest patent validity, enforceability, or infringement through the Biologics Price Competition and Innovation Act patent-exchange process. [4] The relevant disputes can involve manufacturing, formulation, device, and method patents rather than a conventional small-molecule Orange Book patent listing.
What is the Orange Book status of Gonal-f?
Gonal-f is a biologic, and biologic patent information is generally evaluated through FDA biologics and patent-transparency mechanisms rather than the traditional Orange Book framework used for approved small-molecule drugs. The Orange Book is therefore not the principal source for assessing all Gonal-f exclusivity or biosimilar-entry barriers.
Commercial diligence should distinguish among:
- FDA approval status.
- Reference-product exclusivity.
- Patent listings or patent notices.
- Device rights.
- Manufacturing patents.
- State substitution rules.
- Biosimilar interchangeability.
Treating Gonal-f as a conventional Orange Book product can produce an incomplete entry analysis.
How strong is the follitropin alfa patent estate?
The patent estate is moderate for manufacturing and device barriers but weak as a basic molecule-exclusivity barrier.
| Protection category |
Current strategic strength |
| Foundational recombinant FSH patents |
Low, largely expired in major markets |
| Manufacturing process patents |
Moderate |
| Formulation patents |
Low to moderate, depending on jurisdiction and claim scope |
| Pen and delivery-device patents |
Moderate for presentation-specific competition |
| Method-of-use patents |
Low to moderate |
| Regulatory and clinical data package |
Moderate |
| Brand and physician familiarity |
Strong commercial protection |
| Manufacturing know-how |
Strong operational barrier |
The strongest remaining barriers are likely to be process capability, regulatory comparability, device execution, and commercial contracting rather than broad exclusionary patents.
What generic entry risks exist for follitropin alfa?
The main entry risks are biosimilar substitution and price competition, not rapid low-cost generic conversion.
Near-term risk
European markets face the greatest direct competition because multiple follitropin alfa biosimilars are already established. Tendering can reduce net prices even when branded products retain meaningful prescription volume.
Medium-term risk
U.S. risk depends on the appearance of FDA-approved biosimilars, payer adoption, and whether a competitor obtains interchangeable status. A biosimilar without interchangeability can still win through specialty-pharmacy formularies and clinic contracts.
Long-term risk
The broader risk is therapeutic substitution. Clinics may adopt follitropin delta, follitropin beta, or menotropins based on dosing convenience, ovarian-response protocols, reimbursement, or procurement economics.
How does follitropin alfa compare with competing fertility drugs?
| Attribute |
Follitropin alfa |
Follitropin delta |
Follitropin beta |
Menotropins |
| Source |
Recombinant |
Recombinant |
Recombinant |
Urinary-derived |
| Main differentiation |
Established brand and pen delivery |
Individualized dosing |
Established recombinant FSH alternative |
FSH plus LH activity |
| Biosimilar risk |
High in Europe |
Lower as a newer product |
Product-specific |
Generic and urinary-product competition |
| Manufacturing complexity |
High |
High |
High |
High, with biological-source variability |
| Pricing pressure |
High |
Moderate |
High |
High |
| Clinical positioning |
Broad and established |
Personalized ovarian stimulation |
Conventional recombinant FSH |
Patients requiring LH activity or protocol-specific use |
What licensing deals affect the follitropin alfa market?
Commercial rights are often divided by geography. Merck KGaA has used regional affiliates, distributors, and commercial partners for fertility products, while biosimilar products have relied on licensing and commercialization arrangements to reach local markets.
The most relevant deal structures include:
- Regional marketing rights.
- Distribution agreements with fertility specialists.
- Device and pen supply arrangements.
- Manufacturing and technology-transfer agreements.
- Biosimilar co-commercialization.
Public disclosures do not provide a complete, consolidated list of all current Gonal-f licensing and distribution agreements. Revenue exposure should therefore be modeled at the product, geography, and channel level rather than inferred from one global license.
What market dynamics will shape the financial outlook?
The outlook is stable to declining in mature markets and more favorable in underpenetrated fertility markets.
Positive drivers include:
- Continued IVF procedure growth.
- Rising treatment rates in emerging markets.
- Fertility-preservation demand.
- High patient recurrence across multiple cycles.
- Physician familiarity with Gonal-f.
- Expansion of self-injection and pen-based administration.
Negative drivers include:
- European biosimilar penetration.
- Payer pressure on specialty fertility drugs.
- Clinic purchasing consolidation.
- Lower-cost urinary gonadotropins.
- Product substitution within the recombinant FSH class.
- Regulatory and reimbursement restrictions.
- Absence of standalone public revenue disclosure, which limits investor visibility.
The likely financial profile is a mature cash-generating product with declining price realization in competitive markets, partly offset by volume growth in fertility treatment and continued geographic sales.
Key Takeaways
- Follitropin alfa is a mature recombinant FSH franchise led by Gonal-f.
- Foundational molecule patents are largely expired or commercially weak.
- European biosimilar competition is established through Bemfola and Ovaleap.
- U.S. competition is governed by the biosimilar pathway, not conventional generic substitution.
- Gonal-f revenue is not separately disclosed by Merck KGaA.
- Manufacturing, pen devices, regulatory data, and brand familiarity are more important than basic molecule patents.
- Follitropin delta and menotropins create therapeutic-substitution risk.
- The financial outlook is likely stable to declining in mature markets, with growth potential in emerging fertility markets.
- The principal entry risk is gradual price erosion rather than an immediate, unrestricted generic launch.
FAQs
Is follitropin alfa the same as Gonal-f?
Gonal-f is the principal branded product containing follitropin alfa. Other products may contain the same active ingredient but differ in formulation, device, manufacturing process, regulatory status, and market authorization.
Are Bemfola and Ovaleap interchangeable with Gonal-f?
They are biosimilar follitropin alfa products in jurisdictions where they are approved. Interchangeability depends on the applicable regulatory designation and national substitution rules.
Does follitropin alfa have biosimilar competition in the United States?
The U.S. market requires FDA approval under the biosimilar pathway. European approval of Bemfola or Ovaleap does not establish U.S. approval or pharmacy-level interchangeability.
Why has Gonal-f retained commercial value after patent expiry?
Its position reflects physician familiarity, clinical data, pen-device convenience, manufacturing reliability, specialty distribution, and established clinic protocols.
Is follitropin alfa still a growth product?
It is primarily a mature product. Volume can grow with IVF utilization, but net sales growth is constrained by biosimilar competition, reimbursement pressure, and substitution by other gonadotropins.
References
-
European Medicines Agency. (2013). Ovaleap: EPAR product information. European Union.
-
European Medicines Agency. (2014). Bemfola: EPAR product information. European Union.
-
Merck KGaA. (2024). Annual report 2023. Darmstadt, Germany.
-
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. U.S. Department of Health and Human Services.
-
European Medicines Agency. (2016). Rekovelle: EPAR product information. European Union.
